HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen

Vaccine

Volumn 28, Issue 47, 2010, Pages 7556-7562

  Saenz, R ^a   Souza, C da Silva ^b   Huang, C T ^a   Larsson, M ^c   Esener, S ^a,d   Messmer, D ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c LINKÖPING UNIVERSITY   (Sweden)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adjuvants; Dendritic cells; HMGB 1 peptides; Immunotherapy; Vaccine

Indexed keywords

AMINO ACID; ASPARTYLPROLYLASPARAGINYLALANYLPROLYLLYSYLARGINYLPROLYLPROLYLSERYLALANYLPHENYLALANYLPHENYLALANYLLEUCYLPHENYLALANYLCYSTEINYLSERYLGLUTAMIC ACID; FREUND ADJUVANT; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; HP91 PROTEIN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12P70; INTERLEUKIN 6; ISOLEUCYLSERYLGLUTAMINYLALANYLVALYLHISTIDYLALANYLALANYLHISTIDYLALANYLGLUTAMYLISOLEUCYLASPARAGINYLGLUTAMYLALANYLGLYCYLARGININE; LACTATE DEHYDROGENASE; OVALBUMIN; SERYLISOLEUCYLISOLEUCYLASPARAGINYLPHENYLALANYLGLUTAMYLLYSYLLEUCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG MEGADOSE; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOSTIMULATION; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; ANTIGENS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CYTOKINES; FEMALE; HMGB1 PROTEIN; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MICE; MICE, INBRED C57BL; OVALBUMIN; PEPTIDES; SPLEEN;

EID: 77958495785     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.054     Document Type: Article

References (48)

1. Singh M., OHagan D. Advances in vaccine adjuvants. Nat Biotechnol 1999, 17(11):1075-1081.
2. McCluskie M.J., Weeratna R.D. Novel Adjuvant Systems. Curr Drug Targets Infect Disord 2001, 1(3):263-271.
3. Singh M., O'Hagan D.T. Recent advances in vaccine adjuvants. Pharm Res 2002, 19(6):715-728.
4. Kovarik J., Siegrist C.A. The search for novel adjuvants for early life vaccinations: can " danger" motifs show us the way?. Arch Immunol Ther Exp 2001, 49(3):209-215.
5. Chisari F.V., Ferrari C., Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995, 13:29-60.
6. Dredge K., Marriott J.B., Todryk S.M., Dalgleish A.G. Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol Immunother 2002, 51(10):521-531.
7. Xu-Amano J., Kiyono H., Jackson R.J., Statts H.F., Fujihashi K., Burrows P.P., et al. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J Exp Med 1993, 178(4):1309-1320.
8. Engers H., Kieny M.P., Malhotra P., Pink J.R. Third Meeting on novel adjuvants curently in or close to clinical testing world health organization-Organization mondiale de la sante, Fondation Merieux, Annecy France, 7-9 January 2002. Vaccine 2003, 21:3503-3524.
9. De Gregorio E., Tritto E., Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol 2008, 38(8):2068-2071.
10. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 1998, 32(3):155-172.
11. Audibert F.M., Lise L.D. Adjuvants: current status, clinical perspectives and future prospects. Immunol Today 1993, 14(6):281-284.
12. Gupta R.K., Siber G.R. Adjuvants for human vaccines-current status, problems and future prospects. Vaccine 1995, 13(14):1263-1276.
13. Bomford R. Will adjuvants be needed for vaccines of the future?. Dev Biol Stand 1998, 92:13-17.
14. Brewer J.M., Conacher M., Satoskar A., Bluethmann H., Alexander J. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol 1996, 26(9):2062-2066.
15. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002, 20:709-760.
16. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll- like receptor 3. Nature 2001, 413(6857):732-738.
17. Netea M.G., van der Graaf C., Van der Meer J.W., Kullberg B.J. Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. J Leukoc Biol 2004, 75(5):749-755.
18. Takeda K., Kaisho T., Akira S. Toll-like receptors. Annu Rev Immunol 2003, 21:335-376.
19. Petrovsky N., Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004, 82(5):488-496.
20. Weiner G.J., Liu H.M., Wooldridge J.E., Dahle C.E., Krieg A.M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 1997, 94(20):10833-10837.
21. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997, 186(10):1623-1631.
22. Krug A., Towarowski A., Britsch S., et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001, 31(10):3026-3037.
23. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006, 5(6):471-484.
24. Schmidt C. Clinical setbacks for toll-like receptor 9 agonists in cancer. Nat Biotechnol 2007, 25(8):825-826.
25. Telusma G., Datta S., Mihajlov I., et al. Dendritic cell activating peptides induce distinct cytokine profiles. Int Immunol 2006, 18(11):1563-1573.
26. Bianchi M.E. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007, 81(1):1-5.
27. Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418(6894):191-195.
28. Ulloa L., Messmer D. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 2006, 17(3):189-201.
29. Wang H., Vishnubhakat J.M., Bloom O., et al. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 1999, 126(2):389-392.
30. Siegal F.P., Kadowaki N., Shodell M., et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999, 284(5421):1835-1837.
31. Dumitriu I.E., Baruah P., Bianchi M.E., Manfredi A.A., Rovere-Querini P. Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur J Immunol 2005, 35(7):2184-2190.
32. Messmer D., Yang H., Telusma G., et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 2004, 173(1):307-313.
33. Rovere-Querini P., Capobianco A., Scaffidi P., et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004, 5(8):825-830.
34. Park J.S., Svetkauskaite D., He Q., et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004, 279(9):7370-7377.
35. Park J.S., Gamboni-Robertson F., He Q., et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006, 290(3):C917-924.
36. Tsung A., Klune J.R., Zhang X., et al. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med 2007, 204(12):2913-2923.
37. Yu M., Wang H., Ding A., et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006, 26(2):174-179.
38. van Zoelen M.A., Yang H., Florquin S., et al. Role of Toll-Like Receptors 2 and 4, and the receptor for advanced glycation end products (Rage) in Hmgb1 induced inflammation in vivo. Shock 2008.
39. Dumitriu I.E., Baruah P., Valentinis B., et al. Release of high mobility group Box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 2005, 174(12):7506-7515.
40. Huttunen H.J., KujaPanula J., Rauvala H. Receptor for advanced glycation end products (RAGE) signaling induces CREB-dependent chromogranin expression during neuronal differentiation. J Biol Chem 2002, 277(41):38635-38646.
41. Clawson C., Huang C.T., Futalan D., et al. Delivery of a peptide via poly(d,l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity. Nanomedicine 2010.
42. Brazolot Millan C.L., Weeratna R., Krieg A.M., Siegrist C.A., Davis H.L. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci USA 1998, 95(26):15553-15558.
43. Wong B.R., Josien R., Lee S.Y., et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997, 186(12):2075-2080.
44. Loskog A., Totterman T.H. CD40L: a multipotent molecule for tumor therapy. Endocr Metab Immune Disord Drug Targets 2007, 7(1):23-28.
45. Kadowaki N., Ho S., Antonenko S., et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001, 194(6):863-869.
46. Jasani B., Navabi H., Adams M. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 2009.
47. Gurer C., Strowig T., Brilot F., et al. Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses. Blood 2008, 112(4):1231-1239.
48. Trumpfheller C., Caskey M., Nchinda G., et al. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci USA 2008, 105(7):2574-2579.